ZBIO Stock Summary and Trading Ideas (Zenas Biopharma | NASDAQ:ZBIO)

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Zenas Biopharma trades on the NASDAQ stock market under the symbol ZBIO.

As of March 6, 2026, ZBIO stock price climbed to $25.28 with 275,241 million shares trading.

ZBIO has a beta of 0.36, meaning it tends to be less sensitive to market movements. ZBIO has a correlation of 0.00 to the broad based SPY ETF.

ZBIO has a market cap of $1.36 billion. This is considered a Small Cap stock.

Last quarter Zenas Biopharma reported $0 in Revenue and -$1.22 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.24.

The top ETF exchange traded funds that ZBIO belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWN.

ZBIO has outperformed the market in the last year with a price return of +247.7% while the SPY ETF gained +18.7%. However, in the short term, ZBIO had mixed performance relative to the market. It has underperformed in the last 3 months, returning -35.8% vs -1.7% return in SPY. But in the last 2 weeks, ZBIO shares have fared better than the market returning -2.3% compared to SPY -2.5%.

ZBIO support price is $23.82 and resistance is $26.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZBIO shares will trade within this expected range on the day.